CTOs on the Move

MyoKardia

www.myokardia.com

 
Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.myokardia.com
  • 333 Allerton Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.741.0900

Executives

Name Title Contact Details

Funding

MyoKardia raised $46M on 05/01/2015

Similar Companies

Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

VelosBio

VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.

Midwest AgEnergy Group

Midwest AgEnergy Group is a North Dakota biofuels enterprise. Midwest AgEnergy Group owns Blue Flint Ethanol, a 65 million gallon per year biorefinery in operation since 2007 near Underwood, N.D., and Dakota Spirit AgEnergy, a 65 million gallon per year biorefinery east of Jamestown, ND that began production in June 2015. Together with our partners, we are building a renewable energy future for the country, increasing demand for North Dakota farmers, and bringing prosperity to our communities.

Boccard Usa Corporation

Boccard Usa Corporation is a Sugar Land, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.